Continuing Medical Education Articles
Saline instillation before tracheal suctioning decreases the
incidence of ventilator-associated pneumonia*
Pedro Caruso, MD, PhD; Silvia Denari, PhD; Soraia A. L. Ruiz, RT; Sergio E. Demarzo, MD, PhD;
Daniel Deheinzelin, MD, PhD
LEARNING OBJECTIVES
On completion of this article, the reader should be able to:
1. Describe technique for tracheal installation of saline.
2. Explain benefits and outcomes of tracheal installation of saline.
3. Use this information in a clinical setting.
The authors have disclosed that they have no financial relationships with or interests in any commercial companies
pertaining to this educational activity.
All faculty and staff in a position to control the content of this CME activity have disclosed that they have no financial
relationship with, or financial interests in, any commercial companies pertaining to this educational activity.
Lippincott CME Institute, Inc., has identified and resolved all faculty conflicts of interest regarding this educational activity.
Visit the Critical Care Medicine Web site (www.ccmjournal.org) for information on obtaining continuing medical education credit.
Objectives: To compare the incidence of ventilator-associated
pneumonia (VAP) with or without isotonic saline instillation before
tracheal suctioning. As a secondary objective, we compared the
incidence of endotracheal tube occlusion and atelectasis.
Design: Randomized clinical trial.
Setting and Patients: The study was conducted in a medical
surgical intensive care unit of an oncologic hospital. We selected
consecutive patients needing mechanical ventilation for >72 hrs.
Patients were allocated into two groups: a saline group that received
instillation of 8 mL of saline before tracheal suctioning and a control
group which did not. VAP was diagnosed based on clinical suspicion
and confirmed by bronchoalveolar lavage quantitative culture. The
incidence of atelectasis on daily chest radiography and endotracheal
tube occlusions were recorded. The sample size was calculated to a
power of 80% and a type I error probability of 5%.
Measurements and Main Results: One hundred thirty patients
were assigned to the saline group and 132 to the control group.
V
The baseline demographic variables were similar between
groups. The rate of clinically suspected VAP was similar in both
groups. The incidence of microbiological proven VAP was significantly lower in the saline group (23.5% ⴛ 10.8%; p ⴝ 0.008)
(incidence density/1.000 days of ventilation 21.22 ⴛ 9.62; p <
0.01). Using the Kaplan-Meier curve analysis, the proportion of
patients remaining without VAP was higher in the saline group
(p ⴝ 0.02, log-rank test). The relative risk reduction of VAP in the
saline instillation group was 54% (95% confidence interval, 18%–
74%) and the number needed to treat was eight (95% confidence
interval, 5–27). The incidence of atelectases and endotracheal
tube occlusion were similar between groups.
Conclusions: Instillation of isotonic saline before tracheal suctioning decreases the incidence of microbiological proven VAP.
(Crit Care Med 2009; 37:32–38)
KEY WORDS: pneumonia; ventilator-associated pneumonia; prevention; respiratory therapy
entilator-associated pneumonia (VAP) is a frequent mechanical ventilation (MV)
complication associated to
high mortality, morbidity, and cost (1–3).
Management of airway and its secretions,
such as subglottic suctioning (4), manipulations or changes of the ventilator circuit (5,
6), and drainage of ventilator circuit condensate (7) may affect the incidence of VAP.
*See also p. 330.
Medical Doctor (PC, SED), Hospital A C Camargo,
Sao Paulo, SP, Brazil; Medical Doctor (DD), Núcleo
Avançado do Tórax, Hospital Sírio-Libanês, Sao Paulo,
SP, Brazil; and Respiratory Therapist (SD, SR), Hospital
A C Camargo, Sao Paulo, SP, Brazil.
The authors have not disclosed any potential conflicts of interest.
For information regarding this article, E-mail:
pedro.caruso@hcnet.usp.br
Copyright © 2008 by the Society of Critical Care
Medicine and Lippincott Williams & Wilkins
32
DOI: 10.1097/CCM.0b013e3181930026
The isotonic saline instillation before
tracheal suctioning (ISIBTS) represents
an option to dilute and mobilize pulmonary
secretions (8) and is a common practice in
airway management. A national survey in
the United States revealed that 74% of centers have airway management policies incorporating instillation of isotonic saline
(9). Although its use before tracheal suctioning is a common practice, it remains
controversial (10).
Considering VAP incidence, ISIBTS is
a double-edged sword. ISIBTS could inCrit Care Med 2009 Vol. 37, No. 1
crease the incidence of VAP because it
dislodges more viable bacterial colonies
from the endotracheal tube than the insertion of a suctioning catheter without
previous saline instillation (11). Such dislodgement could lead to contamination
of the lower airways. However, ISIBTS
could decrease VAP incidence because it
increases the amount of secretions removed (12), stimulates coughing (13)
that can bring secretions to the trachea
for subsequent suctioning, and also
thins secretions. Another reason for decreased VAP incidence upon ISIBTS is
hypothetical. Given that some authors
consider the endotracheal biofilm as a
reservoir for VAP (14 –16), the frequent
rinsing of the endotracheal tube by saline instillation could potentially decrease it, thereby lessening VAP incidence. In the above context, we
hypothesized that instillation of isotonic saline before tracheal suctioning
could decrease the incidence of VAP.
Since the accumulation of secretions
in the endotracheal tube leads to its obstruction, improved removal of secretions by ISIBTS could avoid tube obstruction. Similarly, better airway secretion
removal by ISIBTS could decrease the
incidence of atelectasis stemming from
secretion.
The primary objective of this study
was to compare the incidence of VAP with
or without tracheal ISIBTS. As a secondary objective, we compared the incidence
of both endotracheal tube obstruction
due to secretion and atelectasis.
MATERIALS AND METHODS
Patients and Study Design. We designed a
randomized clinical trial in a closed medical
surgical intensive care unit (ICU) of a tertiary
oncologic hospital.
We included consecutive patients expected
to receive MV for ⬎72 hrs through an orotracheal or tracheotomy tube, who were older
than 18 yrs and had next of kin agreement.
Exclusion criteria were previous MV within
the last month, MV for ⬎6 hrs before study
enrollment, contraindication to bronchoscopy
and being expected to die or undergo withdrawal of treatment within 48 hrs.
Patients were allocated into two groups. In
the first group, tracheal suctioning was performed without prior saline instillation (control group) whereas in the second group there
was instillation of 8 mL of isotonic saline
before each tracheal suctioning (saline group).
The following variables that could interfere
in the incidence of VAP were recorded: airway
humidification, stress ulcer prophylaxis, antibiotic use, immunosuppression (leukocytes ⬍
Crit Care Med 2009 Vol. 37, No. 1
1.000/mm3, continuous use of corticosteroids
or chemotherapy in the last month), type of
admission, cause of MV, and gastroenteral
feeding tube.
All patients used a closed tracheal suctioning system (Trach-Care 14F, Kimberley-Clark,
Neenah, WI) changed weekly or upon mechanical failure or visible soiling (17). Patients used
heat and moisture exchangers (HME) (Hydrobac
II-Hudson-Gibeck-Durham) changed every 72
hrs (18), except for copious airway secretion,
thick tenacious secretion, hypothermia, hemoptysis (5), or weaning failure attributed to
increased airway resistance (19). In the cases
when HME was contraindicated, humidification was performed with a heated water humidifier. Patients’ bed heads were instructed
to be kept at an angle of 45 degree from the
horizontal. Ventilator circuits were changed
only if the circuits were soiled or mechanically
disrupted (20). Selective decontamination of
the digestive tract, oral decontamination with
antiseptics or continuous aspiration of subglottic contents were not performed in any
patients.
The attending physicians and nurses were
blinded to the study group. Only respiratory
therapists performed and recorded the type or
number of tracheal suctions. If nurses or physicians asked for tracheal suctioning of a patient, those were evaluated and performed by
the respiratory therapist. This was possible
because in our intensive care unit (ICU) there
are respiratory therapists on hand around the
clock. Physicians were asked to order a bronchoscopy with bronchoalveolar lavage upon
clinical suspicion of VAP.
The study was approved by the hospital
ethics committee and an informed consent
was obtained from next of kin.
Tracheal Suctioning Routine and Method.
Aspirations were carried out when any one of
the following situations occurred: visible airway secretion into the endotracheal tube, discomfort or ventilator-patient asynchrony,
noisy breathing, increased peak inspiratory
pressures or decreased tidal volume during
ventilation attributed to airway secretion (8).
Before aspirations, patients were preoxygenated at 100% oxygen for 2 mins (8). In the
saline group, 8 mL of isotonic saline was instilled through the lavage/instillation port of
the closed tracheal suctioning system located
close to the junction with the endotracheal
tube. Aspirations were performed at a negative
pressure of 200 cm H2O for 20 secs, during
which the catheter was gently rotated and
withdrawn. Aspirations in the control group
were identical, except for the absence of saline
instillation.
Diagnosis of Ventilator-Associated Pneumonia. VAP was confirmed only after 48 hrs of
MV. The clinical suspicion of VAP was established when otherwise unexplained new or
worsening pulmonary infiltrates on chest radiograph developed in conjunction with at
least one of the following alterations: fever
(⬎37.8°C), leukocytosis (⬎12.000) or leuko-
penia (⬍4.000) or appearance of purulent tracheal secretion (21). Bronchoalveolar lavage
was performed in the wedge position with 120
mL of sterile saline in six aliquots, of which
the first recovered aliquot was rejected. VAP
was considered only if bronchoalveolar lavage
fluid presented ⱖ104 CFU/mL (22, 23). To
avoid VAP diagnostic misclassification because
of fungal colonization, we considered fungal
VAP only in immunosuppressed patients who
responded to antifungal treatment (24 –26).
The indication, type, and duration of antibiotics were according to the attending physician decisions. If a patient had more than one
episode of VAP only the first was considered.
Chest Radiograph Analysis. For the first
176 patients, daily bed chest radiography was
performed while patients were included in the
protocol. Two pulmonologists with expertise
in intensive care medicine analyzed the chest
radiography and recorded the incidence of
pulmonary, lobar, and segmental atelectasis.
They independently analyzed the chest radiography and both were blinded to the study
group.
Tube obstruction, Change of Heat And Moisture Exchangers, and Closed Tracheal Suctioning
System. The orotracheal or tracheostomy
tubes were considered obstructed by secretion
if they have been clinically suspected and the
substitution of the tube would have reverted
the clinical picture. Macroscopical examination was used to confirm the suspicion. Endotracheal tube obstruction was considered only
if diagnosed by the attending physician.
We recorded the number of HME and
closed tracheal suctioning system changes due
to secretion. Programmed changes were not
considered.
Statistical Analysis. Based on a 50% reduction of VAP incidence (from 30% to 15%), a
significance level of 5% and a power of 80% to
reject the null hypothesis, the ideal number of
patients in each group was 133. Comparisons
between groups were performed using the
Student’s t test for continuous variables and
the chi-square statistic (2) for categorical
variables. The time to occurrence of VAP was
analyzed by the Kaplan-Meier method and
tested by the log-rank test (27, 28).
We performed a logistic regression analysis
to prevent treatment effect from being influenced by covariate imbalances. The dependent
variable was microbiological proven VAP and
five independent variables were elected based
on a p ⬍ 0.2 at univariate analysis: age, immunosuppression, antibiotics at admission,
antibiotics during ICU stay and study group.
Agreement regarding chest radiograph
analysis between both physicians was measured with Cohen’s kappa (-statistic). A value
of 1 indicates perfect agreement whereas a
value of 0 indicates that agreement is no better than chance (29).
Relative risk reduction and the number
needed for treatment were calculated according to standard formulas.
33
Values are expressed in mean ⫾ SD for
continuous variables. All reported p values
are two sided. Statistical analysis was performed using SPSS software (SPSS, Chicago, IL).
RESULTS
Patients. From August 2001 through
December 2004, 493 patients were eligible for the study. One hundred thirty
patients in the saline group, and 132 in
the control group completed the study
(Fig. 1). Patient characteristics at the
study enrollment were similar (Table 1).
The ICU mortality (51.9% for saline and
49.6% for control group; p ⫽ 0.71), MV
(11.2 ⫾ 11.2 for saline and 11.1 days ⫾ 9.0 for
control group; p ⫽ 0.92), and ICU (17.2 ⫾
12.3 for saline and 17.6 days ⫾ 12.8 for control group; p ⫽ 0.77) length of stay were
similar between groups. However, ICU mortality, MV, and ICU length of stay were statistically higher in patients with VAP (Table 2).
After study enrollment, tracheotomy
was performed in 20 patients from each
group (p ⫽ 1.0) and the time to tracheotomy was similar for both groups (12 ⫾ 7.6
for saline and 11 ⫾ 7.4 days for control
group; p ⫽ 0.89).
Ventilator-Associated Pneumonia. In
the control group, 3 patients had more
than 1 episode of VAP (2 with 2 episodes
and 1 with 3 episodes) and in the saline
group 1 patient had 2 episodes of VAP.
The incidence density and proportion
of microbiological proven VAP were significantly higher in the control group
(Table 3). Using the Kaplan-Meier curve
analysis, the proportion of patients remaining without VAP was higher in the
saline group (p ⫽ 0.02, log-rank test)
(Fig. 2). The rate of clinically suspected
VAP was similar in both groups.
The relative risk reduction of VAP in
the saline instillation group was 54%
(95% confidence interval [CI] 18%–74%)
and the number needed to treat was 8
(95% CI 5–27).
In the logistic regression analysis, the
only independent variable associated to
microbiological proven VAP was allocation into the control group (Odds ratio
2.48 关95% CI 1.24 – 4.96兴; p ⫽ 0.010).
The proportion of monomicrobial and
polymicrobial VAP were similar between
groups. Also, the proportions of VAP
caused by Gram-positive cocci, Gramnegative bacilli, and yeast were similar
between groups (Table 4). Since all fungal VAP (n ⫽ 3) occurred in the control
group, we analyzed data excluding these
34
Figure 1. Patients eligible, excluded and included in the study.
Table 1. Patients’ characteristics at study enrollment
Number of patients (%)
Age (yrs)
Male (%)
Causes of mechanical ventilation
Pneumonia (%)
Hypoxemic respiratory failure (%)
Coma (%)
Shock (%)
Neuromuscular disease (%)
Others (%)
PaO2/FIO2
Simplified acute physiologic score II at
intensive care unit admission
Simplified acute physiologic score II at
intubation
Immunosuppression (%)
Leucopenia (⬍1.000/mm3) (%)
Gastric ulcer prophylaxis (%)
Type of gastric ulcer prophylaxis
H2 blocker (%)
Proton pump inhibitor (%)
Nasogastric tube (%)
Chronic obstructive pulmonary disease (%)
Type of airway humidification
Heat and moisture exchange (%)
Heated humidifier (%)
Tracheotomy (%)
p
Total
Saline
Control
262
64.1 ⫾ 15.3
136 (51.9)
130 (49.6)
65 ⫾ 14
66 (50.8)
132 (50.4)
63 ⫾ 16
70 (53.0)
73 (28.0)
76 (29.1)
57 (21.8)
26 (10)
5 (1.9)
24 (9.2)
228 ⫾ 105
52.5 ⫾ 15.6
43 (33.3)
34 (26.4)
26 (20.2)
16 (12.4)
2 (1.6)
8 (6.2)
233 ⫾ 102
52.4 ⫾ 15.0
30 (22.7)
42 (31.8)
31 (23.5)
10 (7.6)
3 (2.3)
16 (12.1)
223 ⫾ 109
52.6 ⫾ 16.1
0.42
0.92
55.1 ⫾ 15.3
55.5 ⫾ 15.0
54.7 ⫾ 15.7
0.65
78 (29.8)
11 (4.2)
208 (80.0)
36 (27.7)
6 (4.6)
102 (79.7)
42 (31.8)
5 (3.8)
106 (80.3)
0.50
0.77
1.00
0.87
74 (35.4)
135 (64.6)
112 (42.9)
49 (18.7)
37 (35.9)
66 (64.1)
56 (43.4)
23 (17.7)
37 (34.9)
69 (65.1)
56 (42.4)
26 (19.7)
257 (98.1)
5 (1.9)
13 (5.0)
128 (98.5)
2 (1.5)
8 (6.2)
129 (97.7)
3 (2.3)
5 (3.8)
0.14
0.85
0.17
0.90
0.75
1.00
0.41
Hypoxemic respiratory failure means hypoxemic respiratory failure excluding pneumonia. Values
are n (%).
patients. This exclusion did not change
the result that ISIBTS decreased the incidence of VAP (2 p ⫽ 0.02 and log-rank
p ⫽ 0.04). There were two cases of VAP
caused by coagulase-negative Staphylococcus, both as polymicrobial VAP, one
associated with Pseudomonas aeruginosa
and the other with Stenotrophomonas
maltophilia.
Tube Obstruction, Heat And Moisture
Exchangers, and Closed Tracheal Suctioning System Changes. Four patients
presented endotracheal tube obstruction
in the control group (one episode each)
and one patient in the saline group (one
episode). However, the difference did not
reach statistical significance (Table 5).
The number of tracheal suctions per
day, HME changes due airway secretions
and tracheal closed system suctioning
changes due airway secretions were similar between groups (Table 5).
Chest Radiograph Analysis. Agreement regarding chest radiograph analysis
between physicians was high (for pulmonary atelectasis -statistic ⫽ 0.80, p ⬍
0.01; for lobar atelectasis -statistic ⫽
0.41, p ⬍ 0.01, and for segmental atelectasis -statistic ⫽ 0.74, p ⬍ 0.01).
The incidence of pulmonary, lobar, and
Crit Care Med 2009 Vol. 37, No. 1
Table 2. Characteristics of patients with and without VAP
Number of patients (%)
Age (years)
Male (%)
Causes of MV
Pneumonia (%)
Hypoxemic respiratory failure (%)
Coma (%)
Shock (%)
Neuromuscular disease (%)
Others (%)
Simplified acute physiologic score II at ICU admission
Simplified acute physiologic score II at intubation
Immunosuppression (%)
Leucopenia (⬍1.000/mm3) (%)
Gastric ulcer prophylaxis (%)
Type of gastric ulcer prophylaxis
H2 blocker (%)
Proton pump inhibitor (%)
Nasogastric tube (%)
Chronic obstructive pulmonary disease (%)
Type of airway humidification
Heat and moisture exchange (%)
Heated humidifier (%)
Tracheotomy at admission (%)
Antibiotics at ICU admission (%)
Antibiotics during ICU stay (%)
Mechanical ventilation length (days)
ICU length (days)
ICU mortality
Total
VAP⫹
VAP⫺
p
262
64 ⫾ 15
136 (51.9)
45 (17.2)
60 ⫾ 14
217 (82.8)
65 ⫾ 15
0.043
73 (28)
76(29.1)
57 (21.8)
26 (10)
5 (1.9)
24 (9.2)
52.5 ⫾ 15.6
55.1 ⫾ 15.3
78 (29.8)
11 (4.2)
208 (80.0)
12 (27.3)
17 (38.6)
5 (11.4)
6 (13.6)
1 (2.1)
3 (6.8)
51.3 ⫾ 15.8
54.2 ⫾ 15.6
17 (37.8)
4 (8.9)
33 (73.3)
61 (28.1)
59 (27.2)
52 (24.0)
20 (9.2)
4 (1.8)
21 (9.7)
52.7 ⫾ 15.5
55.2 ⫾ 15.3
61 (28.1)
7 (3.2)
175 (81.4)
74 (35.4)
135 (64.6)
112 (42.9)
49 (18.7)
12 (36.4)
21 (63.6)
16 (36.4)
11 (24.4)
62 (35.2)
114 (64.8)
96 (44.2)
38 (17.5)
257 (98.1)
5 (1.9)
13 (5.0)
187 (71.4)
258 (98.5)
11.1 ⫾ 10.1
17.4 ⫾ 12.1
132 (50.8)
44 (97.8)
1 (2.2)
3 (6.7)
30 (66.7)
45 (100)
18.2 ⫾ 10.8
25.4 ⫾ 14.9
30 (66.7)
213 (98.2)
4 (1.8)
10 (4.6)
157 (72.4)
213 (98.2)
9.7 ⫾ 9.4
15.7 ⫾ 10.7
104 (47.9)
0.37
0.57
0.69
0.21
0.1
0.22
1.0
0.40
0.29
1.0
0.47
0.47
1.0
⬍0.01
⬍0.01
0.032
VAP⫹, patients who developed ventilator-associated pneumonia; VAP⫺, patients who did not develop ventilator-associated pneumonia.
Hypoxemic respiratory failure means hypoxemic respiratory failure excluding pneumonia. Values are n (%).
Table 3. Incidence of VAP and use of antibiotics
Number of patients (%)
Clinically suspected VAP events (%)
Microbiological proven VAP (%)
Incidence density/1.000 MV days
Early-onset VAP (2–5 days of MV) (%)
VAP between 5 and 10 days of MV) (%)
VAP after 10 days of MV (%)
Patients using antibiotics at intensive
unit care admission (%)
Patients using antibiotics at the day of
clinically suspected VAP (%)
Patients that used antibiotics during
intensive unit care stay (%)
Total
Saline
Control
p
262
74 (28.2)
45 (17.2)
15.44
13 (5.0)
16 (6.1)
16 (6.1)
188 (72.0)
130 (49.6)
32 (24.6)
14 (10.8)
9.62
4 (3.1)
7 (5.4)
3 (2.3)
98 (76.0)
132 (50.4)
42 (31.8)
31 (23.5)
21.22
9 (6.8)
9 (6.8)
13 (9.8)
90 (68.2)
0.22
0.008
0.011
0.98
0.17
0.31
0.17
74 (28.2)
31 (23.8)
38 (28.8)
0.38
258 (98.5)
130 (100)
128 (97)
0.12
VAP, ventilator-associated pneumonia, MV, mechanical ventilation.
Values are n (%).
segmental atelectasis was similar between groups (Table 5).
DISCUSSION
In the present study, the instillation of
isotonic saline before tracheal suctioning
decreased the incidence of microbiological proven VAP. The incidence of endotracheal tube occlusion and atelectasis
were similar between groups.
Crit Care Med 2009 Vol. 37, No. 1
We speculate two reasons upon the
decrease in VAP incidence due to ISIBTS.
The first reason was a probable airway
secretion removal improvement, mainly
due to cough stimulation. The second
reason was a probable decrease in endotracheal tube biofilm.
In patients with VAP, tracheal colonization precedes pneumonia in the majority of patients (30, 31), and microorganisms present in tracheal aspirate and
protected specimen bush are concordant
(32). Trachea can be considered as an
inert passage for microorganisms or as a
reservoir of microorganisms. We consider trachea a significant VAP reservoir
because the mucosal surface area, volume of pooled secretions, and clearance
difficulties are equal or higher in the trachea than in the oropharynx. Considering
trachea as a VAP reservoir, ISIBTS may
decrease the incidence of VAP because it
increases tracheal secretion removal (12).
The reasons for secretion removal improvement after saline instillation are
speculative. Among them, one probable
reason is cough stimulation. The increase
in coughing associated to saline instillation was reported in three previous studies (13, 33, 34). Because of in our ICU we
avoid deep levels of sedation, cough stimulation could have been an important determinant of VAP incidence decrease.
Many authors consider the endotracheal tube biofilm as a reservoir for VAP
(14 –16). We can speculate that the frequent rinsing of the endotracheal tube by
ISIBTS may have decreased the endotracheal tube biofilm, thereby lessening VAP
incidence. However, one study showed
that ISIBTS increased viable bacterial dis35
Figure 2. Kaplan-Meier curve. Probability of remaining free from ventilator-associated pneumonia
(VAP). Log-rank ⫽ 0.02.
Table 4. Microorganisms causing VAP
Number of patients (%)
Type of infection
Monomicrobial VAP (%)
Polymicrobial VAP (%)
Gram-positive cocci
Methicillin-resistant Staphylococcus aureus
Coagulase-negative Staphylococci
Gram-negative bacilli
Pseudomonas aeruginosa
Acinetobacter species
Stenotrophomonas maltophilia
Enterobacteriaceae
Burkholderia cepacia
Candida species
Total
Saline
Control
262
130 (49.6)
132 (50.4)
35 (13.4)
10 (3.8)
11 (8.5)
3 (2.3)
24 (18.2)
7 (5.3)
6
2
1
0
5
2
16
6
8
10
1
3
7
1
3
4
0
0
9
5
5
6
1
3
p
0.99
0.54
0.59
0.25
VAP, ventilator-associated pneumonia.
Values are n (%).
Table 5. Atelectasis, tracheal suctions per day, endotracheal tube obstruction, Heat and moisture
exchange and closed tracheal suction system changes
Number of patients (%)
Endotracheal tube occlusion (%)
Heat and moisture exchange change
due to secretion/100 days of MV
Closed tracheal suctioning system
change due to secretion/100 days
of MV
Tracheal suctions per day
Chest radiograph analysis
Number of patients (%)
Pulmonary atelectasis/100 days of MV
Lobar atelectasis/100 days of MV
Segmental atelectasis/100 days of MV
Total
Saline
Control
p
262
5 (1.9)
9 ⫾ 18
130 (49.6)
1 (0.8)
9 ⫾ 19
132 (50.4)
4 (3.0)
10 ⫾ 18
0.37
0.97
2⫾5
1⫾4
2⫾5
0.41
4.8 ⫾ 1.2
4.7 ⫾ 0.9
4.9 ⫾ 1.4
0.14
174
0.21 ⫾ 2.1
0.39 ⫾ 1.9
39.8 ⫾ 39.6
88 (50.6)
0.13 ⫾ 1.3
0.23 ⫾ 1.6
41.2 ⫾ 40.8
86 (49.4)
0.30 ⫾ 2.8
0.55 ⫾ 2.1
38.4 ⫾ 38.5
0.61
0.26
0.64
MV, mechanical ventilation.
Chest radiograph films for two patients, one from each group, were lost. Values are n (%).
36
lodgement (11). Nevertheless, authors
used a very simple in vitro model that did
not consider the anatomical complexity
of the airways, especially its branching. In
addition, saline instillation was applied
once, and it is possible that subsequent
instillations would dislodge less viable
bacteria than successive suctioning without saline instillation.
An interesting result of the present
study was the proportional decrease in
VAP type (monomicrobial or polymicrobial) and pathogens. This finding corroborates the above hypotheses that a decrease in the microbiological burden in
trachea and/or endotracheal biofilm constitutes the mechanism of VAP decrease.
Further studies are necessary to elucidate the mechanisms of the benefit of
ISIBTS. We believe that a clinical randomized study with a control and saline
group and quantification of the bacterial
tracheal tube biofilm and cough intensity
is necessary.
Although the incidence of microbiological proven VAP was higher in the control group, the incidence of clinically suspected VAP was similar between the
groups. It was not an unexpected result
because we adopted a criterion of low
specificity to the diagnosis of clinically
suspected VAP (radiographic abnormality
plus one of three criteria) leading to
many false-positive results (21) that probably diluted any significant difference between groups.
Higher airway secretion removal in
the saline group could lead to a decrease
in the incidence of atelectases due to secretion plugging. Pulmonary or lobar atelectases are usually obstructive. In our
study, the incidence of pulmonary and
lobar atelectasis in the control group was
more than twice that in the saline group,
but the difference did not reach statistical
significance, probably because the number of events was small. The incidence of
segmental atelectasis was similar between groups. This was expected, because
segmental atelectasis, especially at the
lower lobes, have causes other than secretion plugging, such as increased abdominal pressure, hypoventilation, diaphragm dysfunction, sedation, and the
presence of pleural effusion (35).
As previously speculated, saline instillation could prevent encrustations in the
endotracheal tube (36). Since this speculation sounds plausible, one could expect
a significant decrease in the endotracheal
tube obstruction in the saline group.
There was one episode of endotracheal
Crit Care Med 2009 Vol. 37, No. 1
tube obstruction in the saline group and
four in the control group. However, the
difference did not reach statistical significance, probably because of the small
number of events.
There are concerns about the safety of
ISIBTS, especially the occurrence of hypoxemia. The results are controversial
(37) because some studies did not reveal
hypoxemia in infants (38) or adults (12,
33) subjected to ISIBTS, whereas another
did (39). However, in the latter study the
decrease in arterial hemoglobin saturation, while statistically significant, was
clinically irrelevant given the difference
in saturation was around 1%. Two previous studies have revealed that saline instillation did not cause alterations in
blood pressure or heart rate (33, 38).
In the present study, there was an
apparent lack of impact on patient outcomes such as mortality, MV, and ICU
length of stay. Although one could expect
an impact on these outcomes because of
VAP incidence decrease, it did not occur
because our simple size was calculated to
compare VAP incidence and not mortality
attributed to VAP between groups. In Table 2, we compared the above-mentioned
outcomes between patients with and
without VAP whereby the occurrence of
VAP negatively affected these outcomes.
In the present study, there was a high
ICU mortality, a expected finding because
most of our patients were cancer patients
submitted to MV, a known risk factor for
ICU death in cancer patients (40). Other
studies with similar populations have found
a similar or higher mortality (41, 42).
A limitation of the present study is its
single-center design. Nevertheless, the
incidence (1, 3, 43, 44) and microbiology
(43, 45) of VAP were similar to other
studies. This appraisal is important because, as an oncologic hospital, the presence of immunosuppressed patients was
elevated. Notwithstanding, we did not expect that a high percentage of immunosuppressed would affect our results because VAP has been considered a category
distinct from pneumonia in immunosuppressed patients, given that pathogenesis
differs (46). Besides, the prevalence of
immunosuppression was similar between
groups. It is worthy of note that the
present study was conducted in an ICU
with high incidence of VAP and in patients with long MV length of stay using
HME, so our study requires confirmation
in ICU patients with shorter MV length of
stay, use of heated water humidifiers or
lower incidence of VAP. Another limitaCrit Care Med 2009 Vol. 37, No. 1
tion is the lack of blinding of the respiratory therapists, but we believe that this
did not bias the results, because the ICU
physicians were unaware of the patient
group.
CONCLUSIONS
Instillation of isotonic saline before
tracheal suctioning decreases the incidence of microbiological proven VAP. The
incidence of endotracheal tube obstruction, pulmonary, and lobar atelectasis did
not differ.
ACKNOWLEDGMENTS
We thank all Respiratory Therapists
of the Hospital A C Camargo Intensive
Care Unit: Areta Agostinho, Ana Carolina S. de Oliveira, Ana Cristina Moura
Santos, Ana Luiza Arévalo, Anderson
Vendramine de Lima, Angela Martins
Fernandes, Adriana Larios Nobrega,
Celena Freire Friederich, Christiane
Costa, Daniela Maia, Denise Simão
Carnieli, Diego Brito Ribeiro, Fernanda
Dal’maso, Eliana Louzada, Flávia C. Leite, Karla F. G. Bernal, Flávio Carlos
Cardoso, Gabriela M. Manfrim, Jackeline S. Segarra, Maina Morales, Juliana
Franzotti, Juliana Mesti Mendes, Milena
Trudes de Oliveira, Marcelo Colucci,
Luciana Nunes Titton, Luciane Sato Anitelli, Valéria Lourença Borba and Mariana R. Gazzotti. We also thank Suelene
Aires Franca.
REFERENCES
1. Cook DJ, Walter SD, Cook RJ, et al: Incidence
of and risk factors for ventilator-associated
pneumonia in critically ill patients. Ann Intern Med 1998; 129:433– 440
2. Safdar N, Dezfulian C, Collard HR, et al:
Clinical and economic consequences of ventilator-associated pneumonia: A systematic
review. Crit Care Med 2005; 33:2184 –2193
3. Vincent JL, Bihari DJ, Suter PM, et al: The
prevalence of nosocomial infection in intensive
care units in Europe. Results of the European
Prevalence of Infection in Intensive Care
(EPIC) Study. EPIC International Advisory
Committee. JAMA 1995; 274:639 – 644
4. Valles J, Artigas A, Rello J, et al: Continuous
aspiration of subglottic secretions in preventing ventilator-associated pneumonia.
Ann Intern Med 1995; 122:179 –186
5. Branson RD: The ventilator circuit and ventilator-associated pneumonia. Respir Care
2005; 50:774 –785; discussion 785–777
6. Kollef MH, Shapiro SD, Fraser VJ, et al: Mechanical ventilation with or without 7-day
circuit changes. A randomized controlled
trial. Ann Intern Med 1995; 123:168 –174
7. Craven DE, Goularte TA, Make BJ: Contaminated condensate in mechanical ventilator circuits. A risk factor for nosocomial pneumonia?
Am Rev Respir Dis 1984; 129:625– 628
8. AARC clinical practice guideline. Endotracheal suctioning of mechanically ventilated
adults and children with artificial airways.
American Association for Respiratory Care.
Respir Care 1993; 38:500 –504
9. Sole ML, Byers JF, Ludy JE, et al: A multisite
survey of suctioning techniques and airway
management practices. Am J Crit Care 2003;
12:220 –230; quiz 231–222
10. Raymond SJ: Normal saline instillation before suctioning: helpful or harmful? A review
of the literature. Am J Crit Care 1995;
4:267–271
11. Hagler DA, Traver GA: Endotracheal saline and
suction catheters: Sources of lower airway contamination. Am J Crit Care 1994; 3:444 – 447
12. Bostick J, Wendelgass ST: Normal saline instillation as part of the suctioning procedure:
Effects on PaO2 and amount of secretions.
Heart Lung 1987; 16:532–537
13. Demers RR, Saklad M: Minimizing the harmful effects of mechanical aspiration. Heart
Lung 1973; 2:542–545
14. Adair CG, Gorman SP, Feron BM, et al: Implications of endotracheal tube biofilm for
ventilator-associated pneumonia. Intensive
Care Med 1999; 25:1072–1076
15. Inglis TJ, Millar MR, Jones JG, et al: Tracheal
tube biofilm as a source of bacterial colonization of the lung. J Clin Microbiol 1989;
27:2014 –2018
16. Sottile FD, Marrie TJ, Prough DS, et al: Nosocomial pulmonary infection: Possible etiologic
significance of bacterial adhesion to endotracheal tubes. Crit Care Med 1986; 14:265–270
17. Kollef MH, Prentice D, Shapiro SD, et al:
Mechanical ventilation with or without daily
changes of in-line suction catheters. Am J
Respir Crit Care Med 1997; 156:466 – 472
18. Dreyfuss D, Djedaini K, Gros I, et al: Mechanical ventilation with heated humidifiers or
heat and moisture exchangers: Effects on
patient colonization and incidence of nosocomial pneumonia. Am J Respir Crit Care
Med 1995; 151:986 –992
19. Girault C, Breton L, Richard JC, et al: Mechanical effects of airway humidification devices in difficult to wean patients. Crit Care
Med 2003; 31:1306 –1311
20. Hess DR, Kallstrom TJ, Mottram CD, et al:
Care of the ventilator circuit and its relation
to ventilator-associated pneumonia. Respir
Care 2003; 48:869 – 879
21. Fabregas N, Ewig S, Torres A, et al: Clinical
diagnosis of ventilator associated pneumonia
revisited: Comparative validation using immediate post-mortem lung biopsies. Thorax
1999; 54:867– 873
22. Chastre J, Fagon JY, Bornet-Lecso M, et al:
Evaluation of bronchoscopic techniques for the
diagnosis of nosocomial pneumonia. Am J Respir Crit Care Med 1995; 152:231–240
23. Mayhall CG: Ventilator-associated pneumo-
37
24.
25.
26.
27.
28.
29.
30.
31.
38
nia or not? Contemporary diagnosis. Emerg
Infect Dis 2001; 7:200 –204
Pound MW, Drew RH, Perfect JR: Recent
advances in the epidemiology, prevention,
diagnosis, and treatment of fungal pneumonia. Curr Opin Infect Dis 2002; 15:183–194
el-Ebiary M, Torres A, Fabregas N, et al:
Significance of the isolation of Candida species from respiratory samples in critically ill,
non-neutropenic patients. An immediate
postmortem histologic study. Am J Respir
Crit Care Med 1997; 156:583–590
Rello J, Esandi ME, Diaz E, et al: The role of
Candida sp isolated from bronchoscopic
samples in nonneutropenic patients. Chest
1998; 114:146 –149
Bland JM, Altman DG: Survival probabilities
(the Kaplan-Meier method). BMJ 1998; 317:
1572
Bland JM, Altman DG: The logrank test. BMJ
2004; 328:1073
Chmura Kraemer H, Periyakoil VS, Noda A:
Kappa coefficients in medical research. Stat
Med 2002; 21:2109 –2129
de Latorre FJ, Pont T, Ferrer A, et al: Pattern
of tracheal colonization during mechanical
ventilation. Am J Respir Crit Care Med 1995;
152:1028 –1033
George DL, Falk PS, Wunderink RG, et al:
Epidemiology of ventilator-acquired pneu-
32.
33.
34.
35.
36.
37.
38.
monia based on protected bronchoscopic
sampling. Am J Respir Crit Care Med 1998;
158:1839 –1847
Torres A, el-Ebiary M, Gonzalez J, et al: Gastric
and pharyngeal flora in nosocomial pneumonia
acquired during mechanical ventilation. Am
Rev Respir Dis 1993; 148:352–357
Gray JE, MacIntyre NR, Kronenberger WG:
The effects of bolus normal-saline instillation
in conjunction with endotracheal suctioning. Respir Care 1990; 35:785–790
Jablonski RS: The experience of being mechanically ventilated. Qual Health Res 1994;
4:186 –207
Maffessanti M, Berlot G, Bortolotto P: Chest
roentgenology in the intensive care unit: an
overview. Eur Radiol 1998; 8:69 –78
O’Neal PV, Grap MJ, Thompson C, et al: Level
of dyspnoea experienced in mechanically
ventilated adults with and without saline instillation prior to endotracheal suctioning.
Intensive Crit Care Nurs 2001; 17:356 –363
Blackwood B: Normal saline instillation with
endotracheal suctioning: Primum non nocere (first do no harm). J Adv Nurs 1999;
29:928 –934
Shorten DR, Byrne PJ, Jones RL: Infant responses to saline instillations and endotracheal suctioning. J Obstet Gynecol Neonatal
Nurs 1991; 20:464 – 469
39. Ackerman MH: The effect of saline lavage
prior to suctioning. Am J Crit Care 1993;
2:326 –330
40. Maschmeyer G, Bertschat FL, Moesta KT, et
al: Outcome analysis of 189 consecutive cancer patients referred to the intensive care
unit as emergencies during a 2-year period.
Eur J Cancer 2003; 39:783–792
41. Soares M, Salluh JI, Spector N, et al: Characteristics and outcomes of cancer patients
requiring mechanical ventilatory support
for ⬎24 hrs. Crit Care Med 2005; 33:
520 –526
42. Kress JP, Christenson J, Pohlman AS, et al:
Outcomes of critically ill cancer patients in a
university hospital setting. Am J Respir Crit
Care Med 1999; 160:1957–1961
43. Chastre J, Fagon JY: Ventilator-associated
pneumonia. Am J Respir Crit Care Med 2002;
165:867–903
44. Rello J, Ollendorf DA, Oster G, et al: Epidemiology and outcomes of ventilator-associated pneumonia in a large US database.
Chest 2002; 122:2115–2121
45. Park DR: The microbiology of ventilatorassociated pneumonia. Respir Care 2005; 50:
742–763; discussion 763–745
46. Wunderink RG: Nosocomial pneumonia, including ventilator-associated pneumonia.
Proc Am Thorac Soc 2005; 2:440 – 444
Crit Care Med 2009 Vol. 37, No. 1